Skip to content
Study details
Enrolling now

Arginine Therapy for Pain in Children with Sickle Cell Disease

Emory University
NCT IDNCT02447874ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

21

Study length

about 11 years

Ages

7–21

Locations

2 sites in GA

What this study is about

This trial is testing whether giving extra arginine to children with sickle cell disease will reduce pain, decrease the need for pain medication, or shorten hospital stays. It involves different ways of administering arginine.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Arginine
  • 2.Take Arginine (Continuous)
  • 3.Take Arginine (Loading)

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Therapeutic Nutrients/Minerals/Electrolytes (Biological Macromolecular Activity)

Drug routes

oral (Oral Capsule)

Endpoints

Primary: Pharmacokinetics of IV arginine, measured by plasma arginine concentration over time

Secondary: Apparent clearance of arginine, Area Under the Plasma Concentration -Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration for Arginine, Terminal elimination half-life (t1/2) for arginine